from China 
It is used for the enzymatic hydrolysis of peptide chains, specializing in hydrolysis of peptide bonds, which belongs to peptide endonucleases and has a high hydrolysis yield.
Specificity: Tyr-X, Trp-X, Phe-X (x<>Pro), but its specificity is less than that of trypsin
| Product name | Chinese name | Hanyu Pinyin | English name |
| Chymotrypsin | Midanbaimei | Chymotrypsin | |
| Source content | This strain is a proteolytic enzyme extracted from cow or pig pancreas. Calculated on a dry basis, the activity of chymotrypsin per 1 mg should not be less than 1,000 units. | ||
| Manufacturing requirements | This product should be extracted from quarantine-qualified cattle or pig pancreas, and the production process should comply with the requirements of the current version of "Good Manufacturing Practice for Drugs." | ||
| Character | This product is white or light yellow crystalline powder or amorphous powder. | ||
| Identification |
1 Acidity Take this product, add water to dissolve it and make a solution containing 2 mg per 1 ml. Measure according to the law (2010 edition of Pharmacopoeia, Part II, Appendix VI H). The pH value should be 5.5 to 7.0. |
||
|
2 Clarity and color of solution Take this product, add water to dissolve it and make a solution containing 2mg per 1ml. Check according to the law (2010 edition of Pharmacopoeia, Part II, Appendix IX A and 2010 edition of Pharmacopoeia, Part II, Appendix IX B). The solution should be clear and colorless or almost colorless. |
|||
| category | Proteolytic enzymes. | ||
| Storage | Shade, seal, and store in a cool place. | ||
| Preparations | Chymotrypsin for injection | ||
| Medical examination | Check name | Classification | |
| Chymotrypsin | Blood chemistry test > Enzyme determination | ||
| Drug name | Chymotrypsin |
| English name | Chymotrypsin |
| Alias | Chymotrypsin; alpha-chymotrypsin; Avazyme; Chymar |
| Classification | Respiratory system drugs > Expectorant drugs > Drugs that promote the dissolution of sputum |
| Dosage form | Chymotrypsin for injection is 1mg (800U) per vial; 5mg (4000U). |
| Pharmacological effects | It can cut the peptide chain of protein macromolecules into peptides with smaller molecular weight, or act on the ends of the peptide chain of protein molecules to separate amino acids; it can also hydrolyze certain lipids. Through this action, fibrin and mucin in sputum can be hydrolyzed into peptides or amino acids, liquefying viscous sputum and making it easier to cough up. It is effective for purulent or non-purulent sputum. In addition, chymotrypsin can relax the ciliary ligament and dissolve the protein structure of some tissues in the eye. Chymotrypsin can also promote the penetration of antibiotics and chemotherapy drugs into lesions. |
| Pharmacokinetics | Chymotrypsin and trypsin are both powerful proteolytic enzymes, differing only in their hydrolysis sites. Snake venom neurotoxin contains basic amino acids, which are easily decomposed into non-toxic proteins by chymotrypsin and trypsin, thereby blocking the toxin from entering the bloodstream and causing toxic effects. Chymotrypsin is more effective than trypsin in treating snake bites from the subfamily Acernae, and the combined application of the two enzyme preparations is more effective. |
| Indications | 1). Used in ophthalmology surgery to relax the ciliary ligament and reduce traumatic iridocyclitis; it can also be used in cataract extraction to make the lens easy to remove. |
| 2). Used for wound healing, anti-inflammation and prevention of local edema, blood accumulation, sprain hematoma, edema after breast surgery, otitis media, rhinitis, etc. after trauma or surgery. | |
| 3). Used for the treatment of chronic bronchitis, bronchiectasis or lung abscess, it can liquefy both purulent and non-purulent sputum and make it easier to cough up. | |
| 4). Treatment of poisonous snake bites. | |
| Contraindications | 1). For patients under 20 years old, because the lens capsule and vitreous ligament are firmly connected, the eyeball is small, and the sclera is highly elastic, it may cause vitreous prolapse, or patients with traumatic cataracts whose vitreous humor is not fixed may cause loss of vitreous humor. , so they are all disabled. |
| 2). It is contraindicated in patients with high intraocular pressure or cataracts accompanied by corneal degeneration, as well as those with a tendency of vitreous liquefaction. | |
| 3). It is prohibited for those with severe liver and kidney disease, abnormal coagulation function and those who are taking anticoagulants. | |
| Notes | 1). An allergy test is required before intramuscular injection of chymotrypsin, and intravenous injection is prohibited. |
| 2). If an allergic reaction is caused, use should be stopped immediately and treated with antihistamines. | |
| 3). Chymotrypsin has strong toxicity to the retina. Since it can cause lens damage, do not allow the solution to penetrate into the vitreous body during application. | |
| 4). Chymotrypsin is rapidly inactivated when it encounters blood, so there must be no uncoagulated blood at the site of administration. | |
| 5). Chymotrypsin is relatively stable in the solid state, but its solution is unstable. It will lose 50% of its activity if left at room temperature for 9 days, so it should be prepared before use. | |
| 6). For glaucoma symptoms caused by chymotrypsin, it may be relieved by instilling β-blockers (such as timolol) or oral carbonic anhydrase inhibitors (such as acetazolamide) after surgery. . | |
| 7). Since the titer of chymotrypsin decreases significantly after ultrasonic atomization, the inhalation time of ultrasonic atomization of chymotrypsin should be controlled within 5 minutes. | |
| Adverse reactions | 1). Topical ophthalmic drugs generally do not cause systemic adverse reactions, but they can cause short-term increases in intraocular pressure, leading to eye pain, uveitis and corneal edema. This glaucoma symptom can last for 1 week and then subside. It can lead to linear corneal opacity, vitreous hernia, iris pigment loss, uveitis, wound dehiscence or delayed healing, etc. |
| 2). Blood system: chymotrypsin can cause coagulation dysfunction. | |
| 3). Others: (1) Intramuscular injection may occasionally cause anaphylactic shock. (2) Chymotrypsin can cause the release of histamine, causing pain and swelling at the local injection site. | |
| Usage and dosage | 1). Usually 4000U at a time. Dissolve chymotrypsin in 5ml of sodium chloride injection before use. |
| 2). Administration through the eye: Used in ophthalmology as an enzymatic decomposition of the lens zonule. Dissolve chymotrypsin with sodium chloride injection to make a 1:5000 solution. Inject into the posterior chamber from the pupil. After 2 to 3 minutes, After the crystal floats, rinse it with sodium chloride injection and remove the lens. | |
| 3). Spray inhalation: used to liquefy sputum, and can be made into a 0.05% solution for atomization and inhalation. | |
| 4). Local injection: (1) When dealing with soft tissue inflammation or trauma, a solution of chymotrypsin 800U (1mg) dissolved in 1ml of physiological sodium chloride solution can be injected locally into the wound. (2) For venomous snake bites, chymotrypsin 10 to 20 mg, dilute each tube with 4 ml of water for injection, and inject infiltration around the snake tooth mark, and inject 2 needles in the central area of the wound, and then inject 3 cm above the swelling. 1 to 2 layers of ring sealing, 0.3 to 0.7ml per needle according to different parts, at least 10 needles, up to 26 needles. | |
| 5). External use: (1) For acne vulgaris, apply chymotrypsin locally, twice a day. (2) For chronic skin ulcers, apply chymotrypsin (400 μg/ml) aqueous solution to the wound wetly, 1 to 2 hours each time. |